Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:AVIR NASDAQ:LEGN NASDAQ:NKTR NASDAQ:TPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$19.44-0.5%$18.12$16.10▼$42.47$2.44B0.672.36 million shs1.55 million shsAVIRAtea Pharmaceuticals$3.67-2.9%$3.15$2.46▼$4.15$314.08M0.25325,197 shs311,695 shsLEGNLegend Biotech$38.96-1.9%$32.84$27.34▼$60.87$7.16B0.191.38 million shs824,628 shsNKTRNektar Therapeutics$25.01-0.4%$13.94$6.45▼$37.38$310.30M0.94880,892 shs1.21 million shsTPTXTurning Point Therapeutics$76.01$75.83$23.77▼$82.20$3.81B-0.181.14 million shs4,322 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals+1.67%+8.59%-0.26%+0.57%-47.84%AVIRAtea Pharmaceuticals+0.53%+3.00%+17.39%+39.48%+19.24%LEGNLegend Biotech+0.63%+12.33%+5.50%+24.09%-16.08%NKTRNektar Therapeutics+7.45%+1.83%+121.15%+170.90%+25.81%TPTXTurning Point Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLSApellis Pharmaceuticals4.4396 of 5 stars4.31.00.04.41.92.50.6AVIRAtea Pharmaceuticals3.1753 of 5 stars3.32.00.00.03.22.51.3LEGNLegend Biotech2.9638 of 5 stars4.51.00.00.02.01.70.6NKTRNektar Therapeutics4.6319 of 5 stars3.45.00.04.23.72.50.0TPTXTurning Point TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.62Moderate Buy$39.79104.68% UpsideAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0063.49% UpsideLEGNLegend Biotech 2.91Moderate Buy$72.7086.60% UpsideNKTRNektar Therapeutics 2.86Moderate Buy$88.33253.19% UpsideTPTXTurning Point Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TPTX, APLS, NKTR, LEGN, and AVIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025LEGNLegend BiotechMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$80.00 ➝ $81.007/8/2025LEGNLegend BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.007/8/2025NKTRNektar TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$60.00 ➝ $85.007/2/2025APLSApellis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.007/2/2025LEGNLegend BiotechUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$60.00 ➝ $54.006/24/2025NKTRNektar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $100.006/24/2025NKTRNektar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$120.006/2/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$26.00 ➝ $29.005/22/2025APLSApellis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $41.005/14/2025APLSApellis PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$30.00 ➝ $20.005/14/2025LEGNLegend BiotechTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $71.00(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$781.37M3.13N/AN/A$1.84 per share10.57AVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/ALEGNLegend Biotech$627.24M11.41N/AN/A$5.70 per share6.84NKTRNektar Therapeutics$87.25M3.56N/AN/A$4.94 per share5.06TPTXTurning Point Therapeutics$30.83M123.46N/AN/A$15.84 per share4.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)AVIRAtea Pharmaceuticals-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)NKTRNektar Therapeutics-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)TPTXTurning Point Therapeutics-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/ALatest TPTX, APLS, NKTR, LEGN, and AVIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025LEGNLegend Biotech-$0.18N/AN/AN/A$237.49 millionN/A8/7/2025Q2 2025APLSApellis Pharmaceuticals-$0.44N/AN/AN/AN/AN/A8/6/2025Q2 2025AVIRAtea Pharmaceuticals-$0.44N/AN/AN/AN/AN/A5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.56-$0.40+$0.16-$0.40N/AN/A5/8/2025Q1 2025NKTRNektar Therapeutics-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million5/7/2025Q1 2025APLSApellis Pharmaceuticals-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ATPTXTurning Point TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals2.764.083.62AVIRAtea PharmaceuticalsN/A19.9419.94LEGNLegend Biotech0.305.205.07NKTRNektar TherapeuticsN/A3.243.24TPTXTurning Point TherapeuticsN/A16.8316.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%AVIRAtea Pharmaceuticals86.67%LEGNLegend Biotech70.89%NKTRNektar Therapeutics75.88%TPTXTurning Point Therapeutics90.33%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%AVIRAtea Pharmaceuticals18.10%LEGNLegend Biotech0.02%NKTRNektar Therapeutics5.25%TPTXTurning Point Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770125.68 million117.51 millionOptionableAVIRAtea Pharmaceuticals7085.58 million70.09 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableNKTRNektar Therapeutics22012.41 million11.76 millionOptionableTPTXTurning Point Therapeutics25050.07 million45.77 millionNot OptionableTPTX, APLS, NKTR, LEGN, and AVIR HeadlinesRecent News About These CompaniesTurning Point Therapeutics Inc (TPTX) - Investing.comJune 26, 2025 | investing.comBMS sets up Roche, Pfizer rivalry with Turning Point takeoverMay 20, 2025 | pharmaphorum.comPDigging Into Turning Point USA’s Role in the Trump 2024 Ground GameOctober 8, 2024 | talkingpointsmemo.comTTurning Point of Tampa Now In-Network with Blue Cross Blue Shield InsuranceSeptember 29, 2024 | markets.businessinsider.comDigital therapeutics at a turning point: What we heard at DTx EastSeptember 14, 2024 | pharmaphorum.comPPTC Therapeutics, Inc. (PTCT) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comTG Therapeutics, Inc. (TGTX) Q2 2024 Earnings Call TranscriptAugust 6, 2024 | seekingalpha.comViking Therapeutics, Inc. (VKTX) Q2 2024 Earnings Call TranscriptJuly 25, 2024 | seekingalpha.comGlass System in Turning Point ResidenceApril 2, 2024 | archdaily.comABid to remove prosecutors sets up turning point in Trump’s Georgia caseFebruary 19, 2024 | politico.comPTurning Point Brands Inc.February 17, 2024 | wsj.comAlzheimer’s: A Turning Point?February 12, 2024 | bbc.co.ukTurning Point Brands Inc (TPB)February 10, 2024 | investing.comCormorant Asset Management, LP's Net WorthFebruary 10, 2024 | benzinga.comSolving quadratic equations - EdexcelJanuary 15, 2024 | bbc.co.ukCOP15: A Turning Point for Investor Approaches to BiodiversityDecember 19, 2023 | morningstar.comMTurning Point USA: Are conservatives fighting back on campus?December 16, 2023 | bbc.comBBMS bet looking good as Augtyro approved in ROS1-positive NSCLCNovember 16, 2023 | thepharmaletter.comTPhD Study : Developing an AI-enabled point-of-care monitoring system to detect systemic concentration of therapeutics in bloodOctober 29, 2023 | ulster.ac.ukUA Turning Point for Japan-US Climate Cooperation?October 28, 2023 | thediplomat.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBiotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsBy Nathan Reiff | June 30, 2025View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big GainsNektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?By Leo Miller | June 28, 2025View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?TPTX, APLS, NKTR, LEGN, and AVIR Company DescriptionsApellis Pharmaceuticals NASDAQ:APLS$19.44 -0.09 (-0.46%) Closing price 04:00 PM EasternExtended Trading$19.36 -0.08 (-0.42%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Atea Pharmaceuticals NASDAQ:AVIR$3.67 -0.11 (-2.91%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.05 (+1.34%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Legend Biotech NASDAQ:LEGN$38.96 -0.75 (-1.89%) Closing price 04:00 PM EasternExtended Trading$38.84 -0.12 (-0.30%) As of 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nektar Therapeutics NASDAQ:NKTR$25.01 -0.09 (-0.36%) Closing price 04:00 PM EasternExtended Trading$24.40 -0.61 (-2.44%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Turning Point Therapeutics NASDAQ:TPTXTurning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Will Oracle's Cloud and AI Deals Propel It to New Highs? Enovix Shares Hit 6-Month High; Long-Term Highs to Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.